[新聞稿] 長江生命科技鎮痛藥物研發新里程獲美加及亞洲多地授權進行臨床試驗
2023年1月17日, 長江生命科技 ( 香港)
News Brief: WEX Pharmaceuticals Inc. Enrolls The First Patient In The Phase 2B Clinical Trial Evaluating The Efficacy And Safety Of Halneuron® In The Treatment Of Chemotherapy-Induced Neuropathic Pain
Vancouver, BC (January 3, 2023) – WEX Pharmaceuticals Inc. (“WEX” or the “Company”), a biotechnology company developing Halneuron® (Tetrodotoxin or TTX) for pain, announced that the first patient has been dosed in its Phase 2B clinical trial evaluating the efficacy and safety of Tetrodotoxin in the treatment of Chemotherapy-Induced Neuro…
新闻简报：WEX 在评估 Halneuron® 治疗化疗引起的神经性疼痛的疗效和安全性的 2B 期临床试验中招募了第一位患者
不列颠哥伦比亚省温哥华（2023 年 1 月 3 日）——威克斯药业有限公司（“WEX”或“公司”）
News Brief: Wex Pharmaceuticals Inc. Announces Authorization For The Conduct Of A Chemotherapy-induced Neuropathic Pain Clinical Trial In China, Singapore, Taiwan, Korea, Usa, And Canada
Vancouver, BC (November 30, 2022) – WEX Pharmaceuticals Inc. (“WEX” or the “Company”), a biotechnology company developing Halneuron® (Tetrodotoxin or TTX) for pain, announced that it has received authorizations for its Phase 2B Clinical Trial Applications from the regulatory authorities of China, Singapore, Taiwan, Korea, USA, and Canada.
新闻简报：WEX 获得授权在中国、新加坡、台湾、韩国、美国和加拿大进行化疗引起的神经性疼痛临床试验
不列颠哥伦比亚省温哥华（2022 年 11 月 30 日）——威克斯药业有限公司（“WEX”或“公司”）
News Brief: Wex Pharmaceuticals Inc. Announces A Scientific Poster Presentation At The IASP World Congress On Pain On Its Lead Compound, Halneuron®
Vancouver, BC (September 22, 2022) – WEX Pharmaceuticals Inc. (“WEX” or the “Company”), a biotechnology company developing Halneuron® (Tetrodotoxin or TTX) for pain, announced that a scientific poster on the Company’s lead drug candidate, Halneuron, was presented at the International Association for the Study of Pain (IASP) World Congress on Pain in Toronto, Ontario, on […]